Roche signs pharmacogenomics pact with Lilly
This article was originally published in Clinica
Executive Summary
Roche Diagnostics - under its business unit Roche Molecular Diagnostics - is collaborating with Eli Lilly to develop pharmacogenomics tests that may identify which patients will benefit most from certain cancer drugs. The Basel, Switzerland firm said that the agreement will initially focus on identifying biomarkers thought to influence patients' survival response rates to Lilly's anti-cancer therapies, pemetrexed (Alimta) and gemcitabine (Gemzar). Roche Molecular Diagnostics will develop any resulting companion diagnostic. Both companies will work with genetic profiling company Response Genetics, based in Los Angeles, California.